Cell and Gene Outsourcing

  1. Early Preclinical Development: A Successful Transition To cGMP Manufacturing 12/2/2024

    Explore the development steps that lead to an mRNA construct optimized for your requirements and that meets future-proof cGMP manufacturing requirements, thereby de-risking the development.

  2. Industry-Leading Lentiviral Titers Through Optimized Production Technology 8/28/2023

    See how VirusExpress' technology was optimized to provide industry-leading lentiviral titer and a streamlined approach to accelerate development timelines and de-risk manufacturing.

  3. Bio4C ProcessPad™ Product Overview 5/19/2020

    Introducing Bio4C ProcessPad™ Software, part of the BioContinuum™ Platform.

  4. Cryopreservation Best Practices For Cell & Gene Therapy Source Material 2/26/2024

    Industry experts share their experiences, including why and how cellular source materials are cryopreserved and why experience across cell types and methods matters.

  5. How MilliporeSigma Promotes Quality And Risk Reduction 10/20/2021

    Learn how MilliporeSigma’s new facility was built with quality and risk reduction at the top of mind and its experts have the experience to support large-scale programs through commercialization.

  6. A Rapid, Innovative Approach To Release Testing 12/12/2022

    Innovative molecular methods will allow mAbs manufacturers to deliver critical therapeutic agents to patients faster. Learn about a powerful tool that accelerates bulk harvest testing.

  7. A Faster, More Sensitive Approach To Virus Detection 2/13/2026

    Discover a faster, more sensitive approach to rodent virus detection that offers a targeted NGS workflow to help uncover contaminants traditional assays may miss.

  8. Purity As A Priority: Optimizing Safety Measures For rAAV Therapies 2/11/2025

    Watch to learn how rAAV vectors in gene therapy are addressing manufacturing impurities, risks to patient safety, and analytical methods for detection while aiding sponsors in regulatory compliance.

  9. Pioneering Solutions That Turn Hope Into Reality

    The number of AAV-mediated therapies in clinical trials continues to rise, increasing demand for doses. A scalable platform is crucial to ensure a seamless transfer from pre-clinical to commercial.

  10. Building A Strong Safety Culture In The Biopharmaceutical Industry 1/25/2025

    Explore how fostering a strong safety culture — rooted in accountability, collaboration, and proactive risk management — can drive operational excellence and long-term success in biopharmaceuticals.